Amundi Grows Position in Glaukos Corporation $GKOS

Amundi boosted its stake in shares of Glaukos Corporation (NYSE:GKOS - Free Report) by 96.9% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 227,290 shares of the medical instruments supplier's stock after buying an additional 111,872 shares during the period. Amundi owned approximately 0.40% of Glaukos worth $22,370,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Bessemer Group Inc. increased its position in Glaukos by 133.9% during the 1st quarter. Bessemer Group Inc. now owns 276 shares of the medical instruments supplier's stock valued at $27,000 after buying an additional 158 shares in the last quarter. Whipplewood Advisors LLC increased its position in Glaukos by 3,957.1% during the 1st quarter. Whipplewood Advisors LLC now owns 284 shares of the medical instruments supplier's stock valued at $28,000 after buying an additional 277 shares in the last quarter. First Horizon Advisors Inc. increased its position in Glaukos by 72.9% during the 1st quarter. First Horizon Advisors Inc. now owns 377 shares of the medical instruments supplier's stock valued at $37,000 after buying an additional 159 shares in the last quarter. Versant Capital Management Inc increased its position in Glaukos by 583.9% during the 1st quarter. Versant Capital Management Inc now owns 383 shares of the medical instruments supplier's stock valued at $38,000 after buying an additional 327 shares in the last quarter. Finally, CoreCap Advisors LLC increased its position in Glaukos by 36.4% during the 4th quarter. CoreCap Advisors LLC now owns 750 shares of the medical instruments supplier's stock valued at $112,000 after buying an additional 200 shares in the last quarter. Institutional investors own 99.04% of the company's stock.

Glaukos Stock Performance

Shares of GKOS traded down $4.73 during trading hours on Friday, hitting $82.74. The stock had a trading volume of 883,604 shares, compared to its average volume of 636,786. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.51 and a quick ratio of 4.69. Glaukos Corporation has a 12 month low of $77.10 and a 12 month high of $163.71. The firm has a market capitalization of $4.75 billion, a PE ratio of -50.15 and a beta of 0.77. The stock has a fifty day moving average price of $93.48 and a 200 day moving average price of $95.65.

Glaukos (NYSE:GKOS - Get Free Report) last issued its quarterly earnings data on Wednesday, July 30th. The medical instruments supplier reported ($0.24) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.02. Glaukos had a negative return on equity of 8.59% and a negative net margin of 21.43%.The company had revenue of $124.12 million during the quarter, compared to analyst estimates of $115.49 million. During the same quarter in the previous year, the company posted ($0.52) earnings per share. Glaukos's revenue was up 29.7% compared to the same quarter last year. Glaukos has set its FY 2025 guidance at EPS. Analysts anticipate that Glaukos Corporation will post -1.08 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on GKOS. Zacks Research lowered Glaukos from a "strong-buy" rating to a "hold" rating in a research report on Friday, August 15th. BTIG Research reissued a "buy" rating and issued a $118.00 target price on shares of Glaukos in a report on Wednesday. Mizuho set a $130.00 target price on Glaukos in a report on Thursday, July 31st. Wells Fargo & Company lifted their target price on Glaukos from $86.00 to $92.00 and gave the stock an "equal weight" rating in a report on Thursday, July 31st. Finally, UBS Group lifted their target price on Glaukos from $125.00 to $134.00 and gave the stock a "buy" rating in a report on Thursday, July 31st. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Glaukos currently has an average rating of "Moderate Buy" and an average price target of $124.83.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.